The Ascent of Abbott: Humira Marketer Battles With FDA Over Biosimilars
This article was originally published in RPM Report
Abbott Labs wasn’t considered a serious biologics manufacturer when the biosimilars pathway was first being debated. But with the arthritis treatment Humira now the world’s best-selling pharmaceutical brand, the company has assumed a leadership position just as the biosimilar opportunity is emerging. And what better way to use that new role than by launching an offensive strike against FDA?
You may also be interested in...
Amgen revealed plans to develop and launch biosimilar versions of Abbott’s Humira and Johnson & Johnson’s Remicade – two competitors to its blockbuster anti-TNF Enbrel – during an investor meeting in New York City Feb. 7.
FDA is still awaiting its first biosimilar product application – and there is no reason to expect a flood of products any time soon. The new pathway faces legal, logistical and resource obstacles. But the most important barrier may be the need for a mindset change.
The Supreme Court decision was a decisive victory for the biopharma industry for a number of reasons. But the drama that unfolded in a razor-close decision will continue as new milestones—political and legislative—approach.